Discovering PSPC1 targeted degraders as novel AML therapeutics
Active Grant Awarded Last action
- Award ID
- R01CA299072
- Recipient
-
The University Of Texas Health Science Center At San Antonio UEI C3KXNLTAAY98
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $649,628
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date 7% complete
- Place of performance
- San Antonio, TX 78229, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded The University of Texas Health Science Center At San Antonio a grant with $649,628 obligated on Sep 9, 2026, under Assistance Listing 93.395, Cancer Treatment Research. The award, Grant R01CA299072, funds "Discovering PSPC1 Targeted Degraders as Novel AML Therapeutics." The research pursues small molecule degraders, molecular glue degraders, or PROTACs that target paraspeckle protein component 1 (PSPC1) as a treatment for acute myeloid leukemia (AML). The project summary identifies PSPC1 as an undruggable target because it lacks enzymatic activity or an active site for small molecule inhibitors. The stated discovery strategy begins with structure-guided identification of small molecules, and the source text ends before the remaining elements.
The period of performance runs from the Sep 9, 2026 award date to an ultimate completion date of Aug 31, 2029. Work is performed in San Antonio, TX 78229. The source identifies no sub-recipients.
Description
- Abstract
- Acute myeloid leukemia (AML) is a highly aggressive hematopoietic malignancy, and the 5-year overall survival of AML patients is still very low (~30%). Identification of novel AML therapeutic targets to develop new and more effective AML targeted therapies remains a high unmet medical need. Our recent studies have discovered paraspeckle protein component 1(PSPC1) as a novel target of AML because: (I) human AML cells express higher levels of PSPC1 than their normal counterparts and the levels of its expression in AML cells are inversely correlated with overall survival in AML patients. (II) PSPC1 knockdown (KD) not only suppresses AML cell proliferation by inducing robust differentiation and promoting apoptosis but also abrogates their leukemogenesis in AML xenograft models. In contrast, PSPC1 knockout (KO) has minimal effects on normal hematopoiesis and development in mice. However, PSPC1 is considered an undruggable target because IT lacks enzymatic activity or an active site for small molecule inhibitor discovery. Targeted protein degradation (TPD) with a small molecule degrader (SMD), a molecule glue degrader (MGD), or a proteolysis targeting chimera (PROTAC) has become a very powerful drug discovery platform to develop more specific and effective antitumor agents for undruggable targets. For example, all-trans retinoic acid is an effective therapy for acute promyelocytic leukemia (APL), a distinct subtype of AML, by induction of leukemic cell differentiation via degrading the PML/rarα oncofusion protein. Similarly, thalidomide was repurposed to treat multiple myeloma by acting as a MGD to degrade IKZF1 and 3 via the E3 ligase cereblon. However, the discovery of smds and mgds is very challenging and has been mainly serendipitous. We have creatively developed an innovative strategy to discover PSPC1 smds and mgds, consisting of: (1) structure-guided identification of small molecule binding sites on the PSPC1 homodimer, (2) a high precision virtual screening, (3) a high throughput primary screening with the hibit-PSPC1- reporter assay, and (4) a counter screening with the hibit-PSPC1-theraml shift assay. Using this strategy we have identified several PSPC1 SMD and MGD hits that exhibit potent antileukemic activity by inhibiting proliferation, inducing differentiation, and promoting apoptosis in AML cells. Based on these findings, we hypothesize that PSPC1 is a novel therapeutic target of AML and small molecules that can selectively degrade PSPC1 have the potential to be developed as novel therapeutics for AML. In response to the funding announcement PAR 25-153 entitled "assay development and screening for discovery of chemical probes, drugs or immunomodulators", we plan to test our hypothesis by pursuing the following specific aims: 1) characterization of the mechanism of action (MOA) and specificity of a selective PSPC1 MGD HIT; 2) using artificial intelligence- based large-scale analog searching and ternary complex structure guided virtual screening to facilitate the HIT- to-lead optimization for the HIT; 3) evaluation of the antileukemic activity and normal cell toxicity of selected PSPC1 MGD hits/leads in vitro. PSPC1 has also been implicated in the tumorigenesis of many different types of cancers. Therefore, PSPC1 mgds should have broad applications for cancer and leukemia treatment.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $649,628 |
Quick answers
Who received award R01CA299072?
R01CA299072 was awarded to The University Of Texas Health Science Center At San Antonio by National Cancer Institute (National Institutes of Health) on September 9, 2026.
How much is award R01CA299072 worth?
$649,628 has been obligated on R01CA299072.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award